A short term cost-effectiveness model for oral antidiabetic medicines in Europe.
- 1 January 1998
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 13 (3) , 317-326
- https://doi.org/10.2165/00019053-199813030-00006
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Glibenclamide vs Gliclazide in Type 2 Diabetes of the ElderlyDiabetic Medicine, 1994
- Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with TroglitazoneNew England Journal of Medicine, 1994
- A Desktop Guide for the Management of Non‐insulin‐dependent Diabetes Mellitus (NIDDM): An UpdateDiabetic Medicine, 1994
- Cost-Effectiveness Comparison of Cefepime and Ceftazidime Using Decision AnalysisPharmacoEconomics, 1994
- GliclazideDrugs, 1993
- Biguanides and NIDDMDiabetes Care, 1992
- Sulfonylureas in NIDDMDiabetes Care, 1992
- Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 1992
- Sulphonylureas and hypoglycaemiaBMJ, 1988
- AcarboseDrugs, 1988